Ensign Peak Advisors
MLYS icon

Ensign Peak Advisors’s Mineralys Therapeutics MLYS Stock Holding History

Ensign Peak Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.19M Buy
118,382
+6,192
+6% +$170K 0.01% 654
2026
Q1 		$3.04M Hold
112,190
– – 0.01% 630
2025
Q4 		$4.07M Buy
112,190
+4,550
+4% +$182K 0.01% 558
2025
Q3 		$4.08M Hold
107,640
– – 0.01% 637
2025
Q2 		$1.46M Buy
107,640
+70,147
+187% +$1.02M ﹤0.01% 1036
2025
Q1 		$595K Buy
+37,493
New +$431K ﹤0.01% 1502
2024
Q4 		– Sell
-125,000
Closed -$1.51M – 1719
2024
Q3 		$1.51M Hold
125,000
– – ﹤0.01% 1084
2024
Q2 		$1.46M Hold
125,000
– – ﹤0.01% 1052
2024
Q1 		$1.61M Hold
125,000
– – ﹤0.01% 1020
2023
Q4 		$1.07M Hold
125,000
– – ﹤0.01% 1319
2023
Q3 		$1.19M Hold
125,000
– – ﹤0.01% 1061
2023
Q2 		$2.13M Hold
125,000
– – ﹤0.01% 854
2023
Q1 		$1.96M Buy
+125,000
New +$2.1M ﹤0.01% 863

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ensign Peak Advisors's MLYS Position: Q2 2026 in Review

Ensign Peak Advisors increased its Mineralys Therapeutics (MLYS) stake by 5.5% in Q2 2026, buying an estimated $170K and bringing the position to 118,382 shares worth $3.19M. The position accounts for 0.01% of the portfolio, ranked #654.

Ensign Peak Advisors first reported a position in MLYS in Q1 2023 and has held it in 13 quarters since. The position peaked at $4.08M in Q3 2025. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Ensign Peak Advisors held 118,382 shares of Mineralys Therapeutics worth $3.19M as of Q2 2026.
  • Ensign Peak Advisors bought 6,192 Mineralys Therapeutics shares in Q2 2026, an estimated $170K.
  • Mineralys Therapeutics made up 0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #654 holding.
  • Ensign Peak Advisors first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Ensign Peak Advisors's Mineralys Therapeutics position peaked at $4.08M in Q3 2025.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.